For the Quarter Ending September 2025
North America
• In the United States, the Gabapentin Price Index fell quarter-over-quarter in Q3 2025, influenced by softened cyclohexanone feedstock prices.
• Gabapentin production costs eased in Q3 2025 due to falling cyclohexanone feedstock prices, relieving cost-push inflation.
• Overall US health spending is projected to reach $5.6 trillion in 2025, supporting pharmaceutical demand.
• FDA safety labeling changes for opioids, including gabapentinoid warnings, influenced Gabapentin demand.
• Macroeconomic indicators showed CPI at 3.0% (September 2025) and PPI at 2.6% (August 2025), reflecting inflationary pressures.
• Industrial production rose 0.1% (September 2025), retail sales increased 5.0% (August 2025), indicating economic activity.
• Unemployment was 4.3% (August 2025), with consumer confidence at 96.67 (September 2025), suggesting stable labor and sentiment.
• US natural gas prices rose 32.1% year-over-year in September 2025, increasing energy-intensive production costs.
Why did the price of Gabapentin change in September 2025 in North America?
• Cyclohexanone feedstock prices softened in Q3 2025, directly easing Gabapentin production costs.
• FDA policy changes regarding gabapentinoids influenced Gabapentin demand in the US.
• Rising US natural gas prices in September 2025 increased energy inputs, partially offsetting feedstock relief.
APAC
• In China, the Gabapentin Price Index fell quarter-over-quarter, influenced by contracting producer prices in September 2025.
• Gabapentin production costs decreased in Q3 2025, driven by a 6.1% decline in Cyclohexanone feedstock prices.
• High Cyclohexanone inventories in Q3 2025, due to weak downstream demand, contributed to lower input costs.
• Gabapentin demand outlook remains positive, supported by China's expanding pharmaceutical market and aging population.
• China's Manufacturing Index was contracting in September 2025, indicating a slowdown in overall industrial activity.
• Consumer Price Index (CPI) contracted by 0.3% year-on-year in September 2025, reflecting broader deflationary pressures.
• Retail sales expanded by 3.0% year-on-year in September 2025, suggesting some consumer spending resilience.
• Policy changes, including NRDL updates and streamlined drug registration, support the innovative drug segment's growth.
Why did the price of Gabapentin change in September 2025 in APAC?
• Gabapentin production costs decreased due to a 6.1% decline in Cyclohexanone feedstock prices during Q3 2025.
• High Cyclohexanone inventories in Q3 2025, stemming from weak downstream demand, exerted downward price pressure.
• The Producer Price Index (PPI) contracted by 2.3% year-on-year in September 2025, reflecting broader market deflation.
Europe
• In Germany, the Gabapentin Price Index fell quarter-over-quarter in Q3 2025, due to contracting industrial production and cost containment.
• Gabapentin production costs trended lower in Q3 2025, with producer prices decreasing 1.7% year-on-year in September.
• Gabapentin demand was supported by Germany's pharmaceutical market, with retail sales increasing 0.2% year-on-year.
• The Gabapentin Price Index faced downward pressure from an extended price moratorium freezing prices until 2026.
• German pharmaceutical production volume dropped 0.3% in Q3 2025, 1.5% lower than one year earlier.
• Euro Area chemical imports were EUR 29758.70 million in August 2025; container freight rates fell for eleven weeks.
• Policy changes, including the EU 'pharma package' and German cost containment, are reshaping the pharmaceutical market.
• Consumer Price Index increased to 2.4% year-on-year in September, reflecting low consumer sentiment at -23.5 index points.
• The Manufacturing Index was contracting in Q3 2025, as industrial production decreased 1.0% and unemployment rose to 3.9%.
Why did the price of Gabapentin change in September 2025 in Europe?
• Producer prices decreased 1.7% year-on-year in September 2025, reducing Gabapentin input costs.
• Contracting Manufacturing Index and 1.0% year-on-year industrial production drop dampened demand.
• Germany's upheld pharmaceutical cost containment measures, including discounts, exerted downward pressure.
